Intended for healthcare professionals


Drug for Alzheimer's disease is of little benefit, study shows

BMJ 2004; 329 doi: (Published 01 July 2004) Cite this as: BMJ 2004;329:9
  1. Debashis Singh
  1. London

    Donepezil (Aricept), a cholinesterase inhibitor approved by the National Institute for Clinical Excellence (NICE) for the treatment of Alzheimer's disease, neither slows the onset of the disease nor delays the need for patients to be taken into care, a study published in the Lancet has found (2004;363; 2105-15).

    The five year, double blind, randomised controlled trial conducted by the University of Birmingham and funded …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription